🔗 Share this article US and UK Sign No-Tariff Pact on Pharmaceuticals. Stock image of drug trade. The United Kingdom and the United States have agreed to a landmark commercial pact that will guarantee zero duties on UK drug exports entering the US market. Agreement Details of the Pact In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the public health system. This commitment guarantees that import taxes on these vital products will remain at nothing for a duration of three years. This deal is in response to earlier threats to hike tariffs on branded pharmaceutical imports, with figures floated reaching 100%. "This deal between the United Kingdom reinforces the global environment for innovative medicines and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release noted. Commercial Significance Medicines represent one of the UK's biggest goods shipped to the United States, which is clearly the biggest destination for leading companies like GSK and AstraZeneca. Export figures show that in the one-year period to the end of the third quarter, the UK shipped drugs worth billions to the US. This amount made up a significant portion of total UK exports in that span. "This agreement secures employment, stimulates investment and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary stated. Specific British Pledges The pact involves several key pledges from the United Kingdom: Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by 25%. Boosted Medicine Funding: There is a aim to increase overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years. Payback Limit: The amount manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Last year, repayments exceeded twenty percent. Broader Context The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over spending levels and approval rates. This friction were intensified by arguments that American consumers were paying a premium for the same drugs than patients in the UK and Europe. Recently, several significant manufacturing plans in the UK have been halted or cancelled, while major expansions have been announced toward US facilities. One official stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the past decade.
Stock image of drug trade. The United Kingdom and the United States have agreed to a landmark commercial pact that will guarantee zero duties on UK drug exports entering the US market. Agreement Details of the Pact In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the public health system. This commitment guarantees that import taxes on these vital products will remain at nothing for a duration of three years. This deal is in response to earlier threats to hike tariffs on branded pharmaceutical imports, with figures floated reaching 100%. "This deal between the United Kingdom reinforces the global environment for innovative medicines and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release noted. Commercial Significance Medicines represent one of the UK's biggest goods shipped to the United States, which is clearly the biggest destination for leading companies like GSK and AstraZeneca. Export figures show that in the one-year period to the end of the third quarter, the UK shipped drugs worth billions to the US. This amount made up a significant portion of total UK exports in that span. "This agreement secures employment, stimulates investment and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary stated. Specific British Pledges The pact involves several key pledges from the United Kingdom: Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by 25%. Boosted Medicine Funding: There is a aim to increase overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years. Payback Limit: The amount manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Last year, repayments exceeded twenty percent. Broader Context The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over spending levels and approval rates. This friction were intensified by arguments that American consumers were paying a premium for the same drugs than patients in the UK and Europe. Recently, several significant manufacturing plans in the UK have been halted or cancelled, while major expansions have been announced toward US facilities. One official stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the past decade.